Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25941394 | 1.00 | MAPT (0.55) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| SCHEMBL25937409 | 1.00 | MAPT (0.55) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| SCHEMBL21472007 | 1.00 | MAPT (0.55) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| SCHEMBL25937530 | 1.00 | MAPT (0.55) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL21458445 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL21820362 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL29137577 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL30075404 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL30011876 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL30011295 | 0.99 | MAPT (0.54) | MAPTCRBNDDB1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | MAPT 507/4885CRBN 2808/4885DDB1 750/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | MAPT 741/4885CRBN 3/4885DDB1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.